Featured

cDC1s serve as architects for the formation and maintenance of tumoral TLSs

The presence of tertiary lymphoid structures (TLSs) in tumors is associated with improved outcomes and response to immune checkpoint blockade (ICB). Although the cell populations within these TLSs are well established, the precise contributions...

Subclinical cholestasis is a hallmark of gut dysbiosis causing resistance to cancer immunotherapy

Mallard de La Varende et al. showed that gut dysbiosis following treatment with antibiotics or antibiotic-associated species led to loss of secondary bile acids (BAs), increased tauro-conjugated prima...

A Patient-Derived Screen Identifies HDAC Inhibitors as Enhancers of Phagocytosis and Potent Immunotherapy Partners

Khalaj et al. performed a small molecule screen of FDA-approved compounds on CD11b+ tumor-associated microglia/macrophages isolated from patient GBM, and identified histone deacetylase (HDAC) inhibito...

Tim-3 Sustains Tumor Treg Stability and Function, Limiting Checkpoint Blockade Therapy Efficacy

Banerjee et al. showed that Tim3 expression on tumor-infiltrating Tregs was required for their survival and suppressive function via Akt-FOXO1 signaling. Treg-specific Tim3 deletion in an MC38 model r...

Mutant KRAS peptide vaccine with dual checkpoint blockade in metastatic colorectal cancer: a phase I trial

Wang et al. evaluated a combination of nivolumab, ipilimumab, and mKRAS-VAX (six 21-mer synthetic long peptides targeting common KRAS mutations) in 13 heavily pretreated patients with MMRp/MSS metasta...

See all for this week

Previous Digests

CARM1 inactivation in cDC1s completes the antitumor trifecta

July 22, 2026

Coactivator-associated arginine methyltransferase (CARM1) is an epigenetic enzyme that controls transcription by methylating arginine residues of chromatin-associated proteins. In previous research, deletion or inhibition of CARM1 in tumor cells enhanced their IFNγ production and sensitized them to T cell-mediated...

Turning up the heat: iSBRT and immunotherapy induce immune reprogramming in cold breast tumors in the clinic

July 15, 2026

The tumor immune microenvironment (TIME) of ER+HER2- high-risk early breast cancer is generally immune-cold, which limits immune checkpoint blockade (ICB) responses. Since radiotherapy may modulate the immune response, it may increase ICB efficacy. However, radiotherapy may also activate the...

Tregs versus Tconv: a battle over metastasis in PDAC

July 8, 2026

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive and difficult-to-treat-tumor type with complex immune dynamics and multiple immune evasion mechanisms at different stages of disease. In work recently published in Science Immunology, Schmiechen et al. unraveled the roles of IFNγ-inducible...

See More Digests

Watch ACIR in action

In November 2019, ACIR received the Visionary Award from the Cambridge Chamber of Commerce.

Watch the 3-minute video explaining ACIR's mission and goal:

In September 2020, ACIR was featured in the documentary The American Dream on Bloomberg TV.

Watch the 6-minute segment on the story behind your favorite digest here:

Donate to support researchers

About ACIR

ACIR's mission is to fast-track cancer immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.

Ute Burkhardt

Ed Fritsch

Lauren Hitchings

Gaëlle Llambi

Maartje Wouters

Alex Najibi

Katherine J. Turner

Stan Wolf

Paula Hochman

Shishir Pant

Nathan Suek

Morgan Janes

More About Us

TESTIMONIALS

I'm a big fan of ACIR. I enjoy their weekly newsletters with clear, concise, and insightful summaries, complemented by excellent images. I've even used the images in some of my presentations to explain complex cancer immunotherapy findings. In our rapidly evolving field, their reliable and well-curated updates are invaluable.

— Carl H. June, MD

Richard W. Vague Professor in Immunotherapy; Professor of PL&M; Director, Center for Cellular Immunotherapies; Director, Parker Institute for Cancer Immunotherapy; University of Pennsylvania Perelman School of Medicine. (Supporter since 2025).

Testimonials